当前位置: 首页 >> 检索结果
289. Medications for Opioid Use Disorder in County Jails - Outcomes after Release.
作者: Peter D Friedmann.;Donna Wilson.;Thomas J Stopka.;Dana Bernson.;Ekaterina Pivovarova.;Warren Ferguson.;Randall A Hoskinson.;Rebecca E Rottapel.;Benjamin Bovell-Ammon.;Ayorkor Gaba.;Jake R Morgan.;Thomas Senst.;Edmond Hayes.;Elizabeth A Evans.; .
来源: N Engl J Med. 2025年393卷10期994-1003页
In 2019, seven county correctional facilities (jails) in Massachusetts initiated pilot programs to provide all Food and Drug Administration-approved medications for opioid use disorder (MOUD).
290. Marburg Virus Disease in Rwanda, 2024 - Public Health and Clinical Responses.
作者: Sabin Nsanzimana.;Eric Remera.;Menelas Nkeshimana.;Ryan P Westergaard.;Tsion Firew.;Muhammed Semakula.;Eric Seruyange.;Kara L Neil.;Marrigje Jacoba Kreuger.;Abebe Bekele.;Joseph Biramahire.;Anselme Bizimana.;Brian Chirombo.;Janet Diaz.;Germaine Dushimimana.;William A Fischer.;Thomas E Fletcher.;Robert Fowler.;Michel R Gatera.;Ruggero Giuliani.;Jacob Goldberg.;Fidele Hakorimana.;Richard Hatchett.;Zainab Ingabire.;Lambert Ingabire.;Annick Ishimwe.;Gisele Isingizwe.;Frederique Jacquerioz.;Etienne Kayigi.;Serge Kazindu.;Apollinaire Manirafasha.;Edward J Mills.;Hassan Mugabo.;Isabelle Mukagatare.;Janvier Murayire.;Clarisse Musanabaganwa.;Evariste Mushuru.;Leon Mutesa.;Claude Mambo Muvunyi.;Raissa Muvunyi.;Louise Mwiseneza.;Ernest Nahayo.;Vincent Ndayiragije.;Halifa Ndayisabye.;Gentil Semahoro Ndayishimiye.;Jean Claude S Ngabonziza.;Marie Grace Niwemuhoza.;Nicolas Niyigaba.;Patrick Niyonshuti.;Marie Grace Niyonizeye.;Olivier Nsekuye.;Déo Kimalarungu Ntakambirwa.;Emmanuel Ntawuyirusha.;Jean Baptiste Ntihumbya.;Gaston Nyirigira.;Amanda Rojek.;Athanase Rukundo.;Jean Paul Rwabihama.;Fernand Rwamwejo.;Gloria Shumbusho.;Jean Pierre Sibomana.;David Turatsinze.;Doris Lorette Uwamahoro.;François Xavier Uwimana.;Yvan Butera.;Théogène Twagirumugabe.;Edson Rwagasore.; .
来源: N Engl J Med. 2025年393卷10期983-993页
On September 27, 2024, Rwanda reported an outbreak of Marburg virus disease (MVD), after a cluster of cases of viral hemorrhagic fever was detected at two urban hospitals.
291. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
作者: James Chih-Hsin Yang.;Shun Lu.;Hidetoshi Hayashi.;Enriqueta Felip.;Alexander I Spira.;Nicolas Girard.;Yu Jung Kim.;Se-Hoon Lee.;Yurii Ostapenko.;Pongwut Danchaivijitr.;Baogang Liu.;Adlinda Alip.;Ernesto Korbenfeld.;Josiane Mourão Dias.;Benjamin Besse.;Antonio Passaro.;Ki-Hyeong Lee.;Hailin Xiong.;Soon-Hin How.;Ying Cheng.;Gee-Chen Chang.;Hiroshige Yoshioka.;Michael Thomas.;Danny Nguyen.;Sai-Hong Ignatius Ou.;Sanjay Mukhedkar.;Kumar Prabhash.;Manolo D'Arcangelo.;Jorge Alatorre-Alexander.;Juan Carlos Vázquez Limón.;Sara Alves.;Daniil Stroyakovskiy.;Marina Peregudova.;Mehmet Ali Nahit Şendur.;Ozan Yazici.;Raffaele Califano.;Vanesa Gutiérrez Calderón.;Filippo de Marinis.;Sang-We Kim.;Shirish M Gadgeel.;Scott Owen.;John Xie.;Tao Sun.;Jaydeep Mehta.;Raja Venkatasubramanian.;Mariah Ennis.;Elizabeth Fennema.;Mahesh Daksh.;Amy Roshak.;Julie Man.;Roland E Knoblauch.;Joshua M Bauml.;Mahadi Baig.;Sujay Shah.;Seema Sethi.;Byoung Chul Cho.; .
来源: N Engl J Med. 2025年393卷17期1681-1693页
Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.
|